1. Home
  2. CTM vs SPRO Comparison

CTM vs SPRO Comparison

Compare CTM & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CTM

Castellum Inc.

N/A

Current Price

$0.44

Market Cap

63.1M

Sector

Technology

ML Signal

N/A

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

N/A

Current Price

$1.00

Market Cap

67.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CTM
SPRO
Founded
2019
2013
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
63.1M
67.0M
IPO Year
2022
2017

Fundamental Metrics

Financial Performance
Metric
CTM
SPRO
Price
$0.44
$1.00
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
★ $5.33
AVG Volume (30 Days)
★ 536.1K
316.6K
Earning Date
11-05-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
83.33
★ 111.81
EPS
★ N/A
N/A
Revenue
$52,866,001.00
★ $66,802,000.00
Revenue This Year
$4.94
N/A
Revenue Next Year
$8.17
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
18.10
★ 39.24
52 Week Low
$0.34
$0.96
52 Week High
$1.24
$3.08

Technical Indicators

Market Signals
Indicator
CTM
SPRO
Relative Strength Index (RSI) 39.52 40.58
Support Level $0.34 $0.96
Resistance Level $0.66 $1.27
Average True Range (ATR) 0.04 0.06
MACD -0.00 -0.01
Stochastic Oscillator 50.23 23.21

Price Performance

Historical Comparison
CTM
SPRO

About CTM Castellum Inc.

Castellum Inc is focused on building a successful technology services, solutions, and products company in the areas of cybersecurity, IT, electronic warfare, information warfare, system modernization, and information operations with businesses in the defense, federal, civilian, and commercial markets. Services include intelligence analysis, software development, software engineering, program management, strategic and mission planning, information assurance, cybersecurity and policy support, data analytics, and model-based systems engineering. The company maintains one operating and reportable segment, which is the delivery of products and services in the areas of information technology, electronic warfare, information warfare and cybersecurity in the governmental and commercial markets.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: